Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 9/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 9/20 | 0.56 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.56 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.56 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8153693 | 1.00 | ENPP2 (0.63) | ENPP2LPAR1LPAR3LPAR4LPAR5 | |
| SCHEMBL6338696 | 1.00 | ENPP2 (0.63) | ENPP2LPAR1LPAR3LPAR4LPAR5 | |
| SCHEMBL6336879 | 0.88 | PRKCA (0.58) | ENPP2LPAR1LPAR3RECQLBLM | |
| SCHEMBL6336882 | 0.88 | PRKCA (0.58) | ENPP2LPAR1LPAR3RECQLBLM | |
| SCHEMBL6340267 | 0.86 | PRKCA (0.46) | ENPP2LPAR1LPAR3LPAR4LPAR5 | |
| SCHEMBL6340272 | 0.86 | PRKCA (0.46) | ENPP2LPAR1LPAR3LPAR4LPAR5 | |
| SCHEMBL16520373 | 0.83 | PRKCA (0.42) | ENPP2LPAR1LPAR3RECQLBLM | |
| SCHEMBL16705768 | 0.81 | PRKCE (0.42) | ENPP2LPAR1LPAR3RECQLBLM | |
| SCHEMBL16520369 | 0.81 | PPARG (0.46) | LPAR1 | |
| SCHEMBL16520382 | 0.80 | LPAR1 (0.42) | ENPP2LPAR1LPAR3RECQLBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911553-B1 | Osteoblast-specific mitogens and drugs containing such compounds | ROCHE DIAGNOSTICS GMBH (DE) | 2005-06-28 | — | — | US | disclosed |
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | ESSWEIN ANGELIKA (DE) | 2005-01-20 | — | — | US | disclosed |
| US-6197759-B1 | ADMINISTERING LYSOPHOSPHATIDYLIC ACID DERIVATIVE | ROCHE DIAGNOSTICS GMBH (DE) | 2001-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | LPAR1, LPAR2, LPAR4 | ENPP2 9/4885LPAR1 1/4885LPAR3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.